Dataset Information

Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients.

ABSTRACT: OBJECTIVE:The purpose of this study was to evaluate the relationship between CYP1A1 gene rs1048943 polymorphism and the risk of Iraqi men with prostate cancer. METHODS:In this research, we conducted a population-based approach that intersects high-throughput genotype information from different population of Iraq to estimate the frequency of genotypes associated with prostate cancer responsivenessOur study included a total of 100 patients and 150 healthy controls. rs1048943 genotyping has been investigated in Iraqi men in connection with prostate cancer. RESULTS:We observed that individuals with the rs1048943 GA genotype had an increased risk of prostate cancer relative to those with the AA genotype ( OR 95% CI of 0.449 :95%CI 0.23-0.90; P = 0.002). We found in the dominant model that the rs1048943 GA and GG genotype displayed an increased risk of prostate cancer relative to the AA genotype ( OR 95% CI of 0.680 :95%CI 0.4-1.17; P = 0.018). CONCLUSION:Polymorphism RS 1048943 in the CYP1A1 gene is associated with the risk of developing prostate cancer and is possibly one of the most significant factors in its development.
.

SUBMITTER: Hoidy WH

PROVIDER: S-EPMC7173368 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients.

Hoidy Wisam H WH Jaber Ferdous A FA Al-Askari Mohammed A MA

Asian Pacific journal of cancer prevention : APJCP 20191201 12

<h4>Objective</h4>The purpose of this study was to evaluate the relationship between CYP1A1 gene rs1048943 polymorphism and the risk of Iraqi men with prostate cancer.<h4>Methods</h4>In this research, we conducted a population-based approach that intersects high-throughput genotype information from different population of Iraq to estimate the frequency of genotypes associated with prostate cancer responsivenessOur study included a total of 100 patients and 150 healthy controls. rs1048943 genoty ...[more]

PMID: 31870130

Similar Datasets

Project description:Background and objectiveProstate cancer is one of the most widespread cancers among men throughout the world. In addition, it is the second cause of death after lung cancer. Occurrence of the prostate cancer is variable in various regions of the world. Solely, there are three known risk factors for the prostate cancer, including: Age, inheritance and ethnic origin. ELAC2 protein is a phosphodiesterase enzyme encoded by ELAC2 gene in human. This gene is placed on chromosome 17, and it is believed that product of the mentioned gene is an endonuclease contributed in puberty of mitochondrion's tRNA. From clinical viewpoint, variables of ELAC2 gene such as Ser217Leu and Ala541Thr Missense mutations which are accompanied by hereditary prostate cancer (HPC2).Objective of this study is to investigate Ser217Leu (rs4792311) and Ala541Thr (rs5030739) polymorphisms in the individuals with prostate cancer or those who are suspicious of prostate cancer with family past record/history.Study methodIn this study conducted by case-control method in 2018, 102 men with prostate cancer and 98 men being suspicious of prostate cancer out of 10 families referred to shahid Rajaei Hospital in Tonekabon county to study and check were investigated. After collection of data using questionnaire, sampling from individuals and performance of the rest steps, study of polymorphism was carried out by PCR sequencing technique, and the results were analyzed by Chromas software.FindingOf the total studied 102 individuals, 44 individuals (43.1%) were homozygote for Ser217Leu mutation, 36 individuals (35.2%) were heterozygote and 22 individuals (21.5%) lacked Missense mutation. for Ala541Thr mutation, 18 ones (17.6%) were heterozygote and 84 ones (82.3%) lacked Missense mutation. For Ser217Leu mutation, out of 98 suspicious individuals, 21 individuals (21.4%) were homozygote. 6 individuals (6.1%) were heterozygote and 71 individuals (72.4%) lacked the mutation. For Ala541Thr mutation, 15 ones (15.3%) were homozygote and 84 ones (84.6%) lacked the studied mutation.ConclusionResults of this research showed that, in the individuals with the prostate cancer, there is a relationship between Ser217Leu and Ala541Thr polymorphism of ELAC2 gene and/with prostate cancer, and the suspicious individuals gotten involved in the mutation must take action to prevent this cancer..

Project description:ImportanceRecently, genetic polymorphism in HSD3B1 encoding 3β-hydroxysteroid dehydrogenase-1 has been shown to be associated with oncological outcome when treated with androgen-deprivation therapy (ADT) for prostate cancer. Upfront abiraterone combined with ADT has proved survival benefit. However, its effect on oncological outcome among different ethnicities and in abiraterone treatment remain unclear.ObjectiveTo investigate the significance of missense polymorphism in HSD3B1 gene among men treated with primary ADT or abiraterone.Design, setting, and participantsThis prognostic study included Japanese patients with metastatic hormone-sensitive prostate cancer between June 1993 and July 2005 and with castration-resistant prostate cancer between September 2014 and February 2018. Genome DNA was obtained from patient whole blood samples, and genotyping on HSD3B1 (rs1047303, 1245C) was performed by Sanger sequencing.ExposuresPrimary ADT for metastatic hormone-sensitive prostate cancer and abiraterone for castration-resistant prostate cancer.Main outcomes and measuresThe association of genotype in HSD3B1 with clinicopathological parameters and oncological outcome, including prostate-specific antigen response, progression-free survival, treatment failure-free survival, and overall survival was examined.ResultsOf 203 men, 104 were in the primary ADT cohort (median [interquartile range] age, 72 [67-76] years) and 99 men were in the abiraterone group (median [interquartile range] age, 74 [67-80] years). Most patients carried metastatic lesions in each cohort. Among the cohort of primary ADT, men carrying heterozygous and homozygous variant types in HSD3B1 gene showed higher progression risk (hazard ratio [HR], 2.34; 95% CI, 1.08-4.49; P = .03) but not any-caused death risk (HR, 1.36; 95% CI, 0.52-2.92; P = .50), compared with men carrying homozygous wild type. In contrast, among the abiraterone cohort, men carrying variant type in HSD3B1 gene showed lower progression risk (HR, 0.32; 95% CI, 0.12-0.69; P = .006) and lower all-cause mortality risk (HR, 0.40; 95% CI, 0.13-0.94; P = .04) compared with men carrying homozygous wild type.Conclusions and relevanceThis study showed that HSD3B1 genetic variant is distinctly associated with oncological outcome between primary ADT and abiraterone in Japanese men, suggesting universal significance among different ethnicities in primary ADT, as well as promise as a predictive biomarker of ADT and abiraterone.

Dataset Information

Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients.

Publications

Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets